Pathos AI Secures $237 Million in Series E Financing to Scale Agentic AI Drug Development Platform and Advance Oncology Pipeline

Funding follows rapid portfolio expansion and will power the initiation of a registrational study for AI-identified asset JSKN-016 NEW YORK, NY — October 23, 2026 — Pathos AI, Inc., a clinical-stage AI and technology company advancing its own therapeutic pipeline of drugs, today announced the closing of a $237 million Series E financing round at a post-money valuation of approximately $3 billion. The financing was led by Bristol Myers Squibb (NYSE: BMY), alongside participation from existing investors. The capital raise reflects significant operational momentum driven by Pathos’s proprietary A